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Background: The burden of asthma in Africa is high, and yet the disease is not universally pri-
oritised. Data on allergic asthma and its impact on asthma morbidity are limited in Africa. Our aim
was to describe the distribution of skin prick positivity among asthmatics in Eastern Africa.
Methods: From August 2016 to May 2018, 1671 asthmatic patients were enrolled from Uganda,
Kenya, and Ethiopia as part of the African Severe Asthma Program clinical study. Skin prick testing
was performed at baseline using a panel of 12 allergens, and factors associated with skin prick
reactivity determined.
Results: Of the 1, 671 patients recruited, 71% were female with a median age of 40 years,
93.6% were aged >15 years and the patterns of asthma symptom frequency was intermittent in
2.9%, mild persistent in 19.9%, moderate persistent in 42.6% and severe persistent in 34.6% at
baseline. Self-reported triggers, were dust (92%), cold weather (89%), upper respiratory in-
fections (84%), strong smells (79%) and exposure to tobacco (78%). The majority (90%) of the
participants had at least 1 positive allergen reaction, with 0.9% participants reacting to all the 12
allergens. Participants commonly reacted to house dust mites (66%), Blomia tropicalis (62%),
and the German cockroach (52%). Patients sensitized to more allergens (>2) had significantly
reduced lung function (FEV  80%; p ¼ 0.001) and were more likely to visit the emergency
department due to asthma (p ¼ 0.012). There was no significant relationship between number
of allergens and measures of asthma control, quality of life, and other clinical outcomes. Only
the country of origin was independently associated with atopy among African asthmatics.
Conclusion: There is a high prevalence of skin prick positivity among East African patients with
asthma, with the commonest allergen being house dust mite. Skin reactivity did not correlate well
with asthma severity and poor asthma control. The relation between atopy, measured through skin
prick testing, and measures of asthma control among asthma patients in Eastern Africa is unclear
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Asthma is a chronic lung disorder affecting the
airways, with a complex pathophysiology that in-
volves airway inflammation, intermittent airflow
obstruction, and bronchial hyper-responsive-
ness.1–3 The prevalence of asthma in Africa is
estimated to be between 6 and 12%,4–6 with
national estimates ranging from 2 to 53%.4
Symptoms of asthma may be increased or
worsened by different aeroallergens that the
patients encounter.7 More than 50% of adult
asthma and 80% of childhood asthma has been
reported to be allergic; there is evidence that the
prevalence of allergic asthma is increasing.8 The
allergens act locally in the airways in a classical
type-I hypersensitivity reaction, leading to bron-
chospasm and type-2 allergic inflammation.2,3
Therefore, early allergy testing could be
beneficial in persistent and intermittent asthma
particularly for indoor aeroallergens.
Skin prick testing (SPT) is currently the most
effective diagnostic test to detect immunoglobulin
(Ig) E mediated type-I hypersensitivity reactions
especially in patients with atopic asthma.9,10 SPT is
considered simple, safe and highly sensitive, with
low cost and reproducible results.11,12
Measurement of allergen specific IgE in serum
has been shown to have little advantage over
properly performed SPT.13 SPT has also been
shown to be more sensitive than
radioallergosorbent tests for detection of IgE
reactivity.14 SPT reactions have also been shown
to be associated with patient-reported clinical
symptoms.15
However, most of this evidence base is from
high income settings and few studies have been
carried out in Africa16,17 to explore the distribution
of allergic asthma. The aim of this study was to
describe the allergen sensitivities (atopy) and
factors associated with it among asthmatics
enrolled in the African Severe Asthma Projectin the Eastern Africa.
MATERIALS AND METHODS
Study design
This was a nested cross-sectional study under
the African Severe Asthma Program (ASAP) clinical
study (ClinicalTrials.gov Identifier:
NCT03065920).18,19 ASAP was a prospective
clinical study with the primary objective of
identifying and characterizing severe asthma in
Eastern Africa, in order to understand its
demographic, clinical, physiologic, pathologic,
genomic, and immunologic determinants. ASAP
was a multi-site study conducted at: Makerere
University College of Health Sciences at Mulago
Hospital in Uganda, Kenyatta National Hospital in
Nairobi, Kenya, and Black Lion Hospital, Addis
Ababa College of Health Sciences in Ethiopia.
Study population and inclusion criteria
The study included asthmatics aged 12–70
years, residing within 30 km of the enrolling sites.
Patients with a current/previous doctor diagnosis
of asthma or clinical/treated asthma or wheezing/
whistling breath in the last 12 months were eligible
for enrolments into the study. We excluded pa-
tients with an alternative lung disease (e.g. COPD),
comorbid diseases likely to confound assessment
of asthma (eg, active TB), patients unable to
perform study tests and procedures and pregnant
women.
Study procedures
In patients with a history suggestive of asthma in
the last 12 months, asthma was diagnosed using 2
criteria: clinical diagnosis of asthma by a primary
physician (doctor-diagnosed asthma) and a spiro-
metric lung function test that confirmed presence
of airflow obstruction. After giving informed con-
sent, patients were enrolled and underwent a
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developed clinical review form to collect data on
demographics, asthma symptoms, asthma control,
exposure to outdoor and indoor pollutants, known
asthma triggers, tobacco smoking, vital signs, res-
piratory system physical signs, hospitalisation,
adverse events, and visit to the emergency
department. Detailed procedures for tests such as
lung function tests, stool examinations, and blood
tests were published by Kirenga et al.19 Asthma
control was assessed at each visit using the
asthma control test (ACT).20 In the ACT, good
asthma control was defined as having none of
the following in the last 4 weeks: “night-time
asthma symptoms, asthma symptoms on waking,
need for reliever medication, restriction of day-to-
day activities, days off school or work due to
asthma, and asthma attacks or flare-ups”. ACT was
categorized into a binary variable where
“controlled” was defined as ACT score of  20 and
“uncontrolled” being ACT score <20. Asthma
severity was assessed using the definitions and
diagnostic criteria provided by the WHO.21 The
Asthma Quality of Life Questionnaire (AQLQ) was
used to assess the quality of life of the asthma
patients.22 Blood was collected and tested for
HIV and eosinophil count. Stool was collected
and tested for parasitic infections. Lung function
tests were also performed.Skin prick test procedures
Skin Prick Tests (Immunospec [Pty] Ltd, Johan-
nesburg, Gauteng, South Africa) were performed
at baseline for all patients enrolled into the ASAP
study. SPT were performed and interpreted ac-
cording to published international guidelines.23,24
The procedure was performed in a special clinic
room by a trained team. Allergens included the
following; Aspergillus fumigatus, Mould mix IV
(Penicillium brevicompactum, Penicillium
expansum, Penicillium notatum), house dust mite
mix, soya bean, Blomia tropicalis (tropical house
dust mite), Bermuda grass, dog epithelia, cat
epithelia, German cockroach, egg white, cow
milk, and peanut. These are the presumed
commonest allergens to which patients are
exposed in the African region. Normal saline
served as a negative control while histamine was
the positive control, with a mean wheal diameter
of at least 3 mm being positive test read after15 min of allergen application.25 Wheal size was
recorded on the SPT form. Although the risk for
systemic reactions in SPT is very small,26
necessary emergency measures were ensured to
deal with any systemic allergic reaction or
anaphylaxis.
Quality control for the SPT
The study staff were trained in the SPT proced-
ures and training logs maintained prior to study
initiation as described before.27 The study staff
took a comprehensive patient's history to ensure
that the patients had not been taking
antihistamines or oral steroids in the last 7 days
prior to the SPT. A second reader was called
upon for reactions that were not clear. The
allergen reagents were kept in a refrigerator at 2–
8 C when not in use. The study quality control
officer reviewed the SPT forms and checked
them for completeness and accuracy.
Statistical analysis
Data were analysed using STATA version 14
(STATA, College Station, Texas). Primary data
analysis aimed to describe the distribution of skin
prick positivity and to determine factors associated
with it among studied asthmatics at a 95% confi-
dence interval. The relationship between SPT re-
action and asthma severity/control was also
assessed.
RESULTS
Characteristics of the study population
Between August 2016 and May 2018, 2242 pa-
tients were screened and 1671 consenting patients
who met the inclusion criteria were recruited into
the study with the following study site distribution:
Uganda 821 patients; Kenya 431 and Ethiopia 419
patients. Because the study sites were in urban
areas and recruitment of patients into the study
limited to those who reside within 30 km of the
study sites, enrolled patients were mostly urban
residents (>90%). Therefore, data were not avail-
able to evaluate asthma and allergic sensitisation
in rural vs urban settings. Overall, 71% (1170/1660)
of the participants were female, the whole group
had an overall median age of 40 years (IQR; 26 to
52, n ¼ 1634). The majority of the participants
(20%) were in the age group of 35–44 years. The
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25 years (IQR; 14 to 36, n ¼ 1623). Similarly, most
of our participants were in their young and most
productive age, but with the largest percentage
having moderate and severe persistent asthma.
Among patients with asthma status recorded at
baseline (n ¼ 1649), 2.9% had intermittent, 19.9%
had mild persistent, 42.6% had moderate persis-
tent while 34.6% had severe persistent asthma.
Only 1606/1671 participant's performed spirom-
etry, based on this 66.3% were diagnosed as
having confirmed asthma. Of the 1671 patients,
baseline assessment revealed the following co-
morbidities: rhinosinusitis in 21% (352/1671),
eczema/dermatitis in 7% % (112/1671), while 4%
(63/1671) were infected with HIV infection. Only
0.2% (3/1667) were current smokers, 7% (110/
1667) were former smokers, while the majority
(93% [1554/1667]) had never smoked.The majority
(73% [1221/1664]) of the participants were
exposed to biomass smoke while only 20% used
kerosene for lighting or cooking (Table 1a). In
Table 1b, we present the baseline characteristics
of only those participants (93%) who had full
datasets with all parameters; and the results were
not so different from when everyone was
included in Table 1a.
Self-reported triggers of asthma symptoms
The commonest self-reported triggers of asthma
symptoms among patients recruited in our study
population (n ¼ 1671) were dust (92%), cold
weather (89%), upper respiratory infections (84%),
strong smells (79%), exposure to tobacco (78%),
and strong emotions (50%) Among participants in
whom skin prick test was done (n ¼ 1287), 90%
(1160/1287) had at least 1 self-reported trigger.
Among the 5 patients who had no self-reported
triggers, only the 3 from Kenya had at least 1
allergen positive by skin prick test. The 2 Ethio-
pians who had no self-reported triggers did not
have any reactions with skin prick test.) (Table 2).
Allergen distribution
Overall, 90.4% (1163/1287) of the participants
had at least 1 allergen positive using skin prick test,
with positivity rates of 96% (695/721) in Uganda,
78% (285/364) in Kenya and 91% (183/202) in
Ethiopia. The overall positivity rate for each
allergen was; house dust mite mix (66%), Blomiatropicalis (62%), German cockroach (52%), Asper-
gillus fumigatus (32%), Bermuda grass (31%),
mould mix IV (29%), cat epithelia (28%), dog
epithelia (23%), cow milk (22%), peanut (22%), egg
white (19%), and soya bean (18%). Rates for each
allergen varied widely by country. Fig. 1 and Fig. 2
show the percentage positivity for each allergen
per country for adults and children respectively
(Figs. 1 and 2).
The number of allergens that each participant
reacted to per country were explored.Ten per cent
(124/1287) of the participants did not react to any
of the above allergens included in the panel, while
0.9% (11/1287) reacted to all the 12 allergens
included in the SPT panel. Twenty eight percent of
the participants reacted to more than 5 allergens.
The number of positive allergen reactions per pa-
tient also varied widely across the 3 countries
(Fig. 3).Effect of allergens on asthma morbidity
Ethiopia registered the highest proportion of se-
vere persistent asthmatics (58.37%) followed by
Kenya (37.03%) and least in Uganda (21.61%). The
association between individual allergens and
asthma severity/status and asthma control was
assessed in this cohort. In bivariate analysis, no in-
dividual allergen sensitisation was significantly
associated with asthma status/severity at baseline.
However, in Uganda, mould mix sensitisation was
found significantly more often in severe asthmatics
(p < 0.0001). In addition, the proportions of
A. fumigatus (p¼0.001), housedustmite (p¼0.001),
German cockroach (p ¼ 0.035) and cow milk sensi-
tisation were significantly different by asthma status
withmorepositivesamong intermittentasthmatics in
Uganda. In Kenya, cow milk sensitisation was signif-
icantly more common among moderate asthmatics
(p ¼ 0.05). In Ethiopia, sensitisation to A. fumigatus
(p ¼ 0.014), mould mix (p ¼ 0.042) and house dust
mites (p ¼ 0.043) was significantly more frequent
among moderate asthmatics.
Similarly, in bivariate analysis across the 3
countries, with reference to asthma control (binary
variable; controlled vs uncontrolled) Bermuda
grass (p ¼ 0.049), egg white (p ¼ 0.006) and cow
milk (p ¼ 0.018) sensitisation was significantly
more common among the controlled asthmatics.
In Uganda, none of the allergens were significantly







Gender N ¼ 1660 N ¼ 815 N ¼ 431 N ¼ 414
Female (%) 1170 (70.5) 609 (74.7) 322 (74.7) 239 (57.7)
Age (years) N [ 1634 N [ 810 N [ 430 N [ 394
Median age (IQR) 40 (26 – 52) 31 (20 – 44) 42 (32 – 51) 52 (42 – 60)
Age categories (years) n (%) N [ 1634 N [ 810 N [ 430 N [ 394
12-14 105 (6.4) 81 (10.0) 19 (4.4) 5 (1.3)
15-24 271 (16.6) 211 (26.1) 48 (11.2) 12 (3.1)
25-34 260 (15.9) 167 (20.6) 65 (15.1) 28 (7.1)
35-44 329 (20.1) 154 (19.0) 105 (24.4) 70 (17.8)
45-54 320 (19.6) 99 (12.2) 116 (27.0) 105 (26.7)
55-64 233 (14.3) 76 (9.4) 48 (11.2) 109 (27.7)
65þ 116 (7.1) 22 (2.7) 29 (6.7) 65 (16.5)
Age at first diagnosis of asthma N [ 1623 N [ 813 N [ 400 N [ 413
Median age (IQR) 25 (14 – 36) 20 (10 – 33) 29 (16 – 39) 29 (22 – 36)
Asthma status, n (%) N [ 1649 N [ 819 N [ 424 N [ 406
Intermittent 47(2.9) 16(1.9) 30(7.1) 1(0.3)
Mild persistent 328(19.9) 215(26.3) 78(18.4) 35(8.6)
Moderate persistent 703(42.6) 411(50.2) 159(37.5) 133(32.8)
Severe persistent 571(34.6) 177(21.6) 157(37.0) 237(58.4)
Suffering/ diagnosed with; n (%) N [ 1671 N [ 821 N [ 431 N [ 419
Rhino sinusitis 352 (21.1) 247 (30.1) 88 (20.4) 17 (4.1)
Eczema/dermatitis 112 (6.7) 61 (7.4) 34 (7.9) 17 (4.1)
HIV 63 (3.8) 48 (5.9) 9 (2.1) 6 (1.4)
History of smoking n (%) N [ 1667 N [ 821 N [ 430 N [ 416
Current smoker 3 (0.2) 1 (0.1) 1 (0.2) 1 (0.2)
Former smoker 110 (6.6) 38 (4.6) 37 (8.6) 35 (8.4)
Never 1554 (93.2) 782 (95.3) 392 (91.2) 380 (91.4)
Exposed to biomass smoke n (%) N [ 1664 N [ 821 N [ 428 N [ 415
Yes 1221 (73.4) 643 (78.3) 274 (64.0) 304 (73.3)
Uses kerosene for lighting or
cooking n (%)
N [ 1667 N [ 821 N [ 430 N [ 416
Yes 334 (20.0) 113 (13.8) 144 (33.5) 77 (18.5)
Table 1a. Baseline characteristics of study population for all participants by country. Data presented are n (%) or medians with interquartile ranges
(IQR). N ¼ number of participants with data for each variable
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Gender: Female, n (%) 1106 (71.2) 596 (75.0) 294 (75.0) 216 (58.9)
Age (years), median (IQR) 40 (26-52) 31 (20-44) 42 (32-52) 52 (42-60)
Age categories (years), n (%)
12-14 100 (6.4) 79 (9.9) 16 (4.1) 5 (1.4)
15-24 255 (16.4) 207 (26.0) 38 (9.7) 10 (2.7)
25-34 253 (16.3) 163 (20.5) 63 (16.1) 27 (7.4)
35-44 310 (20.0) 151 (19.0) 93 (23.7) 66 (18.0)
45-54 309 (19.9) 99 (12.5) 110 (28.1) 100 (27.3)
55-64 219 (14.1) 74 (9.3) 44 (11.2) 101 (27.5)
65þ 108 (7.0) 22 (2.8) 28 (7.1) 58 (15.8)
Age at first diagnosis of asthma,
Median (IQR)
25 (14-36) 20 (10-33) 29 (16-39.5) 28 (22-35)
Asthma status, n (%)
Intermittent 44 (2.8) 16 (2.0) 27 (6.9) 1 (0.3)
Mild persistent 315 (20.3) 209 (26.3) 75 (19.1) 31 (8.5)
Moderate persistent 667 (42.9) 399 (50.2) 145 (37.0) 123 (33.5)
Severe persistent 528 (34.0) 171 (21.5) 145 (37.0) 212 (57.8)
Suffering/ diagnosed with, n (%)
Rhino sinusitis 330 (21.2) 240 (30.2) 75 (19.1) 15 (4.1)
Eczema/dermatitis 103 (6.6) 59 (7.4) 28 (7.1) 16 (4.4)
HIV 63 (4.1) 48 (6.0) 9 (2.0) 6 (1.6)
History of smoking, n (%)
Current smoker 3 (0.2) 1 (0.1) 1 (0.3) 1 (0.2)
Former smoker 99 (6.4) 37 (4.7) 33 (8.4) 29 (7.9)
Never 1452 (93.4) 757 (95.2) 358 (91.3) 337 (91.8)
Exposed to biomass smoke, n (%)
Yes 1143 (73.6) 622 (78.2) 251 (64.0) 270 (73.4)
Uses kerosene for lighting or cooking, n (%)
Yes 319 (20.5) 108 (13.6) 139 (35.5) 72 (19.6)
Table 1b. Baseline characteristics of participants with complete datasets by country. Data presented are n (%) or medians with interquartile range
(IQR). N ¼ number of participants with complete data for all variables
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Overall Uganda Kenya Ethiopia
n (%) n (%) n (%) n (%)
N ¼ 1671 N ¼ 821 N ¼ 431 N ¼ 419
Upper respiratory infections 1407 (84.2) 811 (98.8) 252 (58.5) 344 (82.1)
Exposure to household pets/poultry 156 (9.3) 67 (8.2) 75 (17.4) 14 (3.3)
Smoking/exposure to tobacco 1296 (77.6) 771 (94.5) 340 (78.9) 180 (43.0)
Strong emotions 832 (49.8) 500 (60.9) 142 (33.0) 190 (45.4)
Cold weather 1481 (88.6) 725 (88.3) 387 (89.8) 369 (88.1)
Hypertension drugs or aspirin 28 (1.7) 10 (1.2) 15 (3.5) 3 (0.7)
Exercise 723 (43.3) 342 (41.7) 132 (30.6) 249 (59.4)
Dust 1540 (92.1) 789 (96.1) 388 (90.0) 363 (86.6)
Strong smells or perfumes 1323 (79.2) 686 (83.6) 344 (79.8) 293 (69.9)
Exposure at work 56 (3.4) 25 (3.1) 21 (4.9) 10 (2.4)
Other 15 (0.9) 14 (1.7) 0 (0.0) 1 (0.2)
None of the above 5 (0.3) 0 (0.0) 3 (0.7) 2 (0.5)
Table 2. Self-reported triggers by country. Data presented are n (%). N ¼ number of participants with data for each parameter
Volume 13, No. 6, Month 2020 7associated with asthma control. In Kenya, German
cockroach sensitisation was found significantly
more often among the uncontrolled asthmatics
(p ¼ 0.003) while cow milk sensitisation was moreFig. 1 Distribution of allergens in adults. Figure shows the percentag
Participants mostly reacted to house dust mites, Blomia tropicalis andfrequent among controlled asthmatics (p ¼ 0.018).
In Ethiopia, the proportions of those with
A. fumigatus (p ¼ 0.014), Blomia tropicalis
(p ¼ 0.029) and dog epithelia (p ¼ 0.031)e positivity for each allergen per country among adults (16þ years).
the German cockroach
Fig. 2 Distribution of allergens in children. Figure shows the percentage positivity for each allergen per country among adults (12–15
years). Participants mostly reacted to house dust mites, Blomia tropicalis and the German cockroach
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http://doi.org/10.1016/j.waojou.2020.100130sensitisation were more often positives among the
controlled asthmatics.
There was a strong association between the
number of allergens to which a patient was sensi-
tized and the lung function. Patients sensitized to
more allergens had significantly lower lungFig. 3 Percentage positivity of allergens per patient. The number of
Ten percent of the participants did not react to any of the allergens, w
higher degree of atopyfunction (FEV 80%; p ¼ 0.001). Similarly, patients
sensitized to more allergens were more likely to
visit the emergency department due to asthma
(p ¼ 0.012). There was no significant relationship
between number of allergens and asthma control,
quality of life, and other clinical outcomes.positive allergens per patient varied widely across the 3 countries.
hile 1% reacted to all the 12 allergens. Ugandans had a noticeably
Characteristic
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Sex: Female 0.78 0.50–
1.21
0.259
Clinic visit because of asthma 1.3 1.03–
1.06
0.031
Upper respiratory infection 2.21 1.44–
3.39
<0.001





Exposure at work 0.45 0.20–
0.99
0.048
Table 3. Factors associated with allergy among asthmatics in Africa, with the country reference being Uganda. Data presented are odds ratios
(OR), 95% confidence intervals (CI) and P-values. Allergy was defined as presence of sensitisation with a SPT of  3 mm to at least 1 allergen
Volume 13, No. 6, Month 2020 9Factors associated with allergy among African
asthmatics
A crude logistic regression analysis was per-
formed to establish factors associated with atopy
among our cohort of asthmatics. The following
parameters were shown to be significantly associ-
ated with atopy among our cohort of asthmatics in
the crude analysis; country of origin, exposure to
cockroaches, visit to emergency clinic because of
asthma, attacks/exacerbations, courses of oral
steroids prescribed, age, visit to a clinic because of
asthma, upper respiratory infections, exposure at
work, and high blood pressure drugs/pain killers
like aspirin. However, in the adjusted analysis using
a model, only country of origin was independentlyassociated with allergy among our cohort of asth-
matics (Table 3).DISCUSSION
We prospectively demonstrated a high preva-
lence (90%) of atopy (ie, skin prick positivity) in this
Eastern Africa cohort of asthmatic population
across 3 countries. Dust was the most prevalent
self-reported trigger. The participants in this cohort
mostly reacted to house dust mites, the tropical
mite Blomia tropicalis and the German cockroach.
Patients sensitized to more allergens had signifi-
cantly reduced lung function and were more likely
to visit the emergency department due to asthma.
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actions for all the allergens followed by Kenyans
and the least reactions were recorded in Ethiopia.
Only country of origin was independently associ-
ated with allergy among our cohort of asthmatics.
Some allergens were also significantly associated
with severity at baseline. More studies are needed
to explore allergic asthma in Africa.
The high prevalence (90%) of skin prick reac-
tivity observed in this study was similar to what has
been reported before by other studies in different
countries. A recent study done in Uganda to esti-
mate the prevalence of atopic sensitisation among
women, revealed a 70% (14/20) skin reactivity
among asthmatics and 32% (37/117) among con-
trols.28 A similar study done among Malaysian
asthmatic patients with and without rhinitis
showed that 68% were reactive to at least 1 of
the aeroallergens.29 An earlier case control study
carried out among 576 asthmatics and 144
healthy controls in Puerto Rico showed that 86%
of the asthmatics had at least 1 positive skin
reaction.30 A similar study done in Jeddah, Saudi
Arabia among 151 asthma patients gave a 75%
skin reactivity to at least 1 allergen; but without a
control group.31 However, in the current study,
there was no clear explanation to why Uganda
had the highest rates of sensitisation. This might
be related to the climate, pollution, humidity, and
other metrological factors that are specific to
each country.
The asthmatics enrolled in this study mostly
reacted to house dust mite, Blomia tropicalis and
the German cockroach. House dust allergens were
earlier shown to be associated with childhood
atopic asthma.32,33 Over 50% of children
sensitized to house dust mite have asthma.34 This
observation may be similar in adults.35 A study
done in Brazil among asthmatic children similarly
showed a high reactivity to both
Dermatophagoides pteronyssinus and
B. tropicalis and recommended environmental
control of house dust mite exposure. In this
study, Dermatophagoides farinae was found in
very low levels (<0.5 mg/g).36 A dust-free
bedroom was considered as 1 of the practical
and effective methods for decreasing asthma in
children with house dust mite allergy.37 However,
recent evidence shows that this method is
clinically ineffective in adults with asthma.38Sensitivity to house dust mite has a very strong
independent association with current asthma, but
not asthma severity.39 However, recent evidence
shows that exposure to house dust mite allergens
is not associated with asthma in childhood.40 In
fact, the chemical and physical methods used to
reduce exposure to house dust mite allergens
are not recommendable.41 This sensitisation
against house dust mites may translate into
increased prevalence of allergic airway diseases.42
Similarly, the German cockroach was associated
with severe persistent asthma at base line in Kenya.
Cockroaches are known to produce many proteins
that induce IgE antibody responses with a high
reactivity using skin prick test and potential cross-
reactivity with mite allergens.43 German
cockroach feces have also been shown to be rich
in allergens.44 Exposure and sensitisation to
these cockroach allergens is associated with
increased asthma morbidity especially among
African American and Hispanic populations.45
In the current study, we registered a relatively
high prevalence of skin reactivity to Aspergillus
fumigatus (32%) and the mould mix IV (29%).
Mould mix was the only allergen that was associ-
ated with the characteristic of severe persistent
asthma at baseline, but only in Uganda. Fungal
allergy has been known to be associated with
worse asthma control, leading to asthma attacks,46
additional need for corticosteroids,
hospitalisation47 and increased rates of
bronchiectasis (especially due to A. fumigatus).48–
50 However, other studies too have demonstrated
a weak association between Aspergillus
sensitisation and asthma severity.51 The skin prick
test panel used in the current study did not
include other relevant fungal allergens such as
Alternaria and Cladosporium species. The mould
mix too was composed of 3 Penicillium species
only (P. brevicompactum, P. expansum,P.
notatum). Besides, the index of clinical suspicion
for fungal infections is very low in Uganda.52,53 A
recent review investigating the burden of fungal
asthma in Africa showed that the prevalence of
fungal allergy was high (3–52%) in adult
asthmatics in Africa with an average of 28% and
a pooled estimate of 23%. This was mostly
caused by Aspergillus species, followed by
Alternaria species (6–40%), Cladosporium species
(4–42%) and the mould mix (7–11%).6 The review
Volume 13, No. 6, Month 2020 11estimated that approximately 4 million adult
asthmatics have fungal sensitisation in Africa. For
future studies, Alternaria species and
Cladosporium species need to be investigated in
the African population.
Dust was the commonest self-reported trigger in
this cohort across the 3 countries. This was prob-
ably because majority of the participants resided in
the busy urban areas where the levels of dust
pollution are highest. Urbanisation and air pollu-
tion with dust and other substances have been
implicated in the increasing burden of asthma in
Africa.4,54
Surprisingly, food allergies were significantly
associated with mild forms of asthma at baseline.
In addition, patients sensitized to more allergens
had significantly reduced lung function and were
more likely to visit the emergency department due
to asthma. Therefore, with a potential increase in
the disability-adjusted life years due to allergic
asthma, this is expected to have serious negative
impact on the developing economies for the
different African countries.
Over 70% of the participants were female and
there was no significant relationship between
gender and allergy. This difference could have
introduced bias because of differences in cigarette
or other noxious agent exposures, although >90%
of participants had never smoked. The median age
at first diagnosis of asthma of 25 years was rela-
tively high; which may be the result of late pre-
sentation and/or poor health seeking habits rather
than late on-set. It is significant to note that we did
not probe specifically for time of onset of symp-
toms which is among the limitations of this study.
The poor health seeking habits in Africa are
especially seen among male participants.55
Previous studies have shown mean age at first
diagnosis of asthma to range from 2.6 to 16
years,56–59 which is lower than the 25 years in
our cohort.
Unbiased cohort studies indicate that asthma
can be thought of as a series of disease clusters, in
which atopy is variably represented. Incompletely
understood polygenetic determinants no doubt
influence the expression of atopy while clinical
asthma severity is thought to occur through the
interplay of genetics, microbial exposures, and
multiple environmental factors, which include butare not limited to aeroallergens and pollutants.60–
62 Similarly, the median eosinophil counts were
normal across the 3 countries and 10% of our
participants did not react to any of the allergens
included in the panel. Stool tests were performed
to check parasitic infections, and all these were
negative for all participants. It is still unclear why
some patients have allergic asthma and others
do not, although there is an apparent genetic
vulnerability.63 In this case, interventions that
decrease vulnerability to air pollution in
genetically susceptible individuals may have a
role in personalized asthma management. Other
allergic comorbidities like rhinosinusitis (21%)
and eczema/dermatitis (7%) were also registered
in this population. However, previous studies
have shown that rhinosinusitis occurs in 75–90%
of allergic asthmatics and 80% of those with non-
allergic asthma.64
The main limitation to the study is that the re-
sults presented in this study were from 3 East Af-
rican countries and the conclusions may not be
applicable to all African countries or even the
entire country in which the study was undertaken –
because this was a single center study in each
country. In this paper we only present base line
data pending determination of the relationship
between atopic sensitisation and response to
optimized treatment. The diagnosis of severe
asthma at baseline was based on symptom and
clinical events recall which may have introduced
biases. There is a significant difference between
the percentage of male and female population,
and this may be a bias for risk factors. The majority
(>90%) of our participants resided in the urban
areas of their respective countries and thus there is
still an information lacuna about skin prick reac-
tivity and asthma characteristics between urban
and rural populations.CONCLUSION
There is a high prevalence of skin prick positivity
among East African patients with asthma with the
commonest allergen being house dust mite. Skin
reactivity did not correlate well with asthma
severity and poor asthma control. The relation
between atopy, measured through skin prick
testing, and measures of asthma control among
12 Kwizera et al. World Allergy Organization Journal (2020) 13:100130
http://doi.org/10.1016/j.waojou.2020.100130asthma patients in Eastern Africa is unclear and
needs further study.
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